Results of a new study show that patients guided to targeted therapy based on ctDNA get the same benefits as those who got tissue-based tests in initial clinical trials.
N-of-One will provide treatment strategies and clinical trial opportunities for patients based on Inivata's ctDNA liquid biopsy test.
Inivata has completed the analytical validation of its 35-gene ctDNA test and plans to conduct clinical validation studies from labs in North Carolina and the UK.
The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.
Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.
In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.
Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.